Obeticholic Acid – Bezafibrate Combination Granted Orphan Drug Designation for Primary Biliary Cholangitis (PBC)
source: pixabay.com

Obeticholic Acid – Bezafibrate Combination Granted Orphan Drug Designation for Primary Biliary Cholangitis (PBC)

  In mid-May 2023, Pharmaceutical Technology reported that a new combination treatment had earned Orphan Drug designation. This combo? Obeticholic acid (OCA) and bezafibrate. Together, they represent a potential therapeutic…

Continue Reading Obeticholic Acid – Bezafibrate Combination Granted Orphan Drug Designation for Primary Biliary Cholangitis (PBC)